{"id":59931,"date":"2024-02-28T06:24:29","date_gmt":"2024-02-28T06:24:29","guid":{"rendered":"https:\/\/medsname.com\/opiprol\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"opiprol","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/opiprol\/","title":{"rendered":"Opiprol"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Opiprol?<\/h3>\n
\n

Opiprol<\/strong> obsahuje opipramol 50 mg<\/strong> od v\u00fdrobce s certifikac\u00ed WHO-GMP (Sun Pharma) \u2014 atypick\u00e9 anxiolytikum p\u0159\u00edbuzn\u00e9 TCA<\/strong> s prim\u00e1rn\u00edm vyu\u017eit\u00edm p\u0159i generalizovan\u00e9 \u00fazkostn\u00e9 poru\u0161e (GAD) a somatoformn\u00edch poruch\u00e1ch<\/strong>. Na rozd\u00edl od klasick\u00fdch TCA opipramol ne<\/strong> neinhibuje zp\u011btn\u00e9 vychyt\u00e1v\u00e1n\u00ed monoamin\u016f. Jeho mechanismus je zalo\u017een p\u0159edev\u0161\u00edm na agonistick\u00e9m p\u016fsoben\u00ed na sigma-1 a sigma-2 receptory<\/strong> plus H1<\/sub> antihistaminikum a slab\u00e9 D2 antagonismu. Standardn\u00ed d\u00e1vkov\u00e1n\u00ed: 50\u2013150 mg\/den<\/strong> ve 1\u20133 d\u00edl\u010d\u00edch d\u00e1vk\u00e1ch. N\u00e1stup \u00fa\u010dinku: 1\u20133 t\u00fddny. Uv\u00e1d\u011bn na trh p\u0159edev\u0161\u00edm v N\u011bmecku, \u0160v\u00fdcarsku, Rakousku a \u010d\u00e1stech v\u00fdchodn\u00ed Evropy<\/strong> jako Insidon<\/strong>. Neschv\u00e1leno FDA \u2014 nen\u00ed dostupn\u00e9 v USA nebo UK jako licencovan\u00fd p\u0159\u00edpravek. Ni\u017e\u0161\u00ed anticholinergn\u00ed z\u00e1t\u011b\u017e ne\u017e u klasick\u00fdch TCA.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

D\u016fle\u017eit\u00e9 \u2014 nejedn\u00e1 se o l\u00e9k na situa\u010dn\u00ed \u00fazkost.<\/strong> Opiprol je anxiolytikum p\u0159\u00edbuzn\u00e9 tricyklick\u00fdm antidepresiv\u016fm (agonista sigma-receptor\u016f)<\/strong>, p\u0159edepisov\u00e1n a titrov\u00e1n po t\u00fddny pro generalizovan\u00e1 \u00fazkostn\u00e1 porucha (GAD), somatoformn\u00ed poruchy a adjuvantn\u00ed l\u00e9\u010dba deprese v zem\u00edch, kde je schv\u00e1len<\/strong>. Nen\u00ed ne<\/strong> spr\u00e1vn\u00fdm l\u00e9kem pro akutn\u00ed, v\u00fdkonov\u011b souvisej\u00edc\u00ed \u00fazkost (l\u00e9t\u00e1n\u00ed, ve\u0159ejn\u00e9 vystupov\u00e1n\u00ed, zkou\u0161ky) \u2014 pro tyto p\u0159\u00edpady jsou klinicky vhodn\u011bj\u0161\u00ed betablok\u00e1tory (propranolol), benzodiazepiny nebo hydroxyzin. Pokud nem\u00e1te diagnostikovanou poruchu n\u00e1lady, \u00fazkostnou nebo psychiatrickou poruchu, neza\u010d\u00ednejte s u\u017e\u00edv\u00e1n\u00edm tohoto l\u00e9ku.<\/div>\n
FDA \u010dern\u00e9 varov\u00e1n\u00ed \u2014 sebevra\u017eednost.<\/strong> V\u0161echna antidepresiva nesou \u010dern\u00e9 varov\u00e1n\u00ed FDA pro zv\u00fd\u0161en\u00e9 riziko sebevra\u017eedn\u00e9ho my\u0161len\u00ed a chov\u00e1n\u00ed u d\u011bt\u00ed, dosp\u00edvaj\u00edc\u00edch a mlad\u00fdch dosp\u011bl\u00fdch do 25 let, zejm\u00e9na b\u011bhem prvn\u00edch t\u00fddn\u016f l\u00e9\u010dby nebo po zm\u011bn\u00e1ch d\u00e1vkov\u00e1n\u00ed. \u010clenov\u00e9 rodiny a p\u0159edepisuj\u00edc\u00ed l\u00e9ka\u0159i by m\u011bli pe\u010dliv\u011b sledovat zhor\u0161en\u00ed n\u00e1lady, agitovanost nebo sebevra\u017eedn\u00e9 my\u0161lenky v t\u00e9to v\u011bkov\u00e9 skupin\u011b.<\/div>\n

Co je Opiprol?<\/h2>\n

Opiprol jsou peror\u00e1ln\u00ed tablety opipramol dihydrochlorid 50 mg<\/strong> vyr\u00e1b\u011bn\u00e9 spole\u010dnost\u00ed Sun Pharma. Opipramol je tricyklick\u00e1 slou\u010denina strukturn\u011b p\u0159\u00edbuzn\u00e1 imipraminu, ale farmakologicky velmi odli\u0161n\u00e1 \u2014 v\u00fdznamn\u011b neinhibuje zp\u011btn\u00e9 vychyt\u00e1v\u00e1n\u00ed serotoninu ani noradrenalinu. M\u00edsto toho je to vysoce afinitn\u00ed agonista sigma-1 a sigma-2 receptor\u016f<\/strong> se sekund\u00e1rn\u00edm H1<\/sub>- antihistaminikum a slab\u00fd antagonista D2 receptor\u016f. Klinicky se pou\u017e\u00edv\u00e1 od roku 1961 (zaveden jako Insidon<\/strong> firmou Geigy) a z\u016fst\u00e1v\u00e1 standardn\u00edm ambulantn\u00edm anxiolytikem v n\u011bmecky mluv\u00edc\u00edch zem\u00edch.<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n
    \n
  • Generalizovan\u00e1 \u00fazkostn\u00e1 porucha (GAD)<\/strong> \u2014 hlavn\u00ed klinick\u00e9 pou\u017eit\u00ed<\/li>\n
  • Somatoformn\u00ed poruchy<\/strong> \u2014 somatizace, p\u0159etrv\u00e1vaj\u00edc\u00ed funk\u010dn\u00ed somatick\u00e9 p\u0159\u00edznaky<\/li>\n
  • Pomocn\u00e1 l\u00e9\u010dba u lehk\u00e9 a\u017e st\u0159edn\u011b t\u011b\u017ek\u00e9 deprese s v\u00fdraznou \u00fazkost\u00ed<\/li>\n
  • Nespavost sekund\u00e1rn\u00ed k \u00fazkosti<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nTypick\u00fd<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    GAD, somatoformn\u00ed<\/td>\n50 mg ve\u010der \u00d7 3\u20135 dn\u00ed<\/td>\n50\u2013150 mg\/den v 1\u20133 d\u00e1vk\u00e1ch<\/td>\n300 mg\/den<\/td>\nV\u011bt\u0161ina l\u00e9ka\u0159\u016f p\u0159edepisuje 50\u2013100 mg ve\u010der nebo 50 mg + 100 mg r\u00e1no + ve\u010der<\/td>\n<\/tr>\n
    \u00dazkost s nespavost\u00ed<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n50\u2013100 mg p\u0159ed span\u00edm<\/td>\n150 mg na noc<\/td>\nSedace vrchol\u00ed 2\u20133 hodiny po pod\u00e1n\u00ed<\/td>\n<\/tr>\n
    Star\u0161\u00ed pacienti<\/td>\n25\u201350 mg ve\u010der<\/td>\n50\u2013100 mg\/den<\/td>\n150 mg\/den<\/td>\nNi\u017e\u0161\u00ed c\u00edlov\u00e1 d\u00e1vka; vy\u0161\u0161\u00ed citlivost na sedaci a ortostatickou hypotenzi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

    Profil ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
    Frekvence<\/th>\n\u00da\u010dinek<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    B\u011b\u017en\u00e9<\/td>\nSedace, \u00fanava<\/td>\nVhodn\u00e9 pod\u00e1vat p\u0159ed span\u00edm; denn\u00ed d\u00e1vkov\u00e1n\u00ed m\u016f\u017ee b\u00fdt limituj\u00edc\u00ed<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nSucho v \u00fastech<\/td>\nM\u00edrn\u00e1 anticholinergn\u00ed z\u00e1t\u011b\u017e \u2014 ni\u017e\u0161\u00ed ne\u017e u imipraminu nebo amitriptylinu<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nP\u0159\u00edr\u016fstek hmotnosti (m\u00edrn\u00fd)<\/td>\nH1<\/sub> stimulace chuti k j\u00eddlu<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nZ\u00e1vrat\u011b, m\u00edrn\u00e1 ortostatick\u00e1 hypotenze<\/td>\nOpatrnost p\u0159i rychl\u00e9m vst\u00e1v\u00e1n\u00ed, zejm\u00e9na u star\u0161\u00edch pacient\u016f<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nZ\u00e1cpa, rozmazan\u00e9 vid\u011bn\u00ed<\/td>\nAnticholinergn\u00ed<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nProdlou\u017een\u00ed QT intervalu<\/td>\nOpatrnost p\u0159i kombinaci s l\u00e9ky prodlu\u017euj\u00edc\u00edmi QT interval<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nHyponatr\u00e9mie, p\u0159echodn\u00e9 zv\u00fd\u0161en\u00ed jatern\u00edch enzym\u016f<\/td>\nMonitorovat p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Interakce s l\u00e9\u010divy<\/h2>\n

    Vyvarovat se kombinace s inhibitory MAO<\/strong> \u2014 14denn\u00ed vyplachovac\u00ed interval, a\u010dkoli riziko serotoninov\u00e9ho syndromu je n\u00edzk\u00e9 vzhledem k absenci aktivity SERT.<\/p>\n

    Aditivn\u00ed deprese CNS<\/strong>: alkohol, benzodiazepiny, opioidy, antihistaminika \u2014 kombinujte opatrn\u011b.<\/p>\n

    Prodlou\u017een\u00ed QT intervalu<\/strong>: opatrnost p\u0159i u\u017e\u00edv\u00e1n\u00ed citalopramu (vysok\u00e1 d\u00e1vka), fluorochinolon\u016f, kvetiapinu, ondansetronu.<\/p>\n

    Anticholinergn\u00ed z\u00e1t\u011b\u017e<\/strong>: aditivn\u00ed \u00fa\u010dinek s difenhydraminem, oxybutyninem, trihexifenidylem.<\/p>\n

    \u010casto kladen\u00e9 dotazy<\/h2>\n

    Jak dlouho trv\u00e1, ne\u017e Opiprol za\u010dne \u00fa\u010dinkovat?<\/h3>\n

    N\u011bkte\u0159\u00ed pacienti pozoruj\u00ed zlep\u0161en\u00ed \u00fazkosti a sp\u00e1nku ji\u017e b\u011bhem 1\u20132 t\u00fddn\u016f; pln\u00fd \u00fa\u010dinek u generalizovan\u00e9 \u00fazkostn\u00e9 poruchy (GAD) se obvykle projev\u00ed po 4\u20136 t\u00fddnech pravideln\u00e9ho u\u017e\u00edv\u00e1n\u00ed.<\/p>\n

    Je Opiprol skute\u010dn\u00fdm antidepresivem?<\/h3>\n

    Strukturn\u011b pat\u0159\u00ed mezi tricyklick\u00e1 antidepresiva, ale farmakologicky p\u016fsob\u00ed sp\u00ed\u0161e jako anxiolytikum. Jeho prim\u00e1rn\u00ed schv\u00e1len\u00e9 pou\u017eit\u00ed v Evrop\u011b je pro GAD a somatoformn\u00ed poruchy, nikoli pro klasickou depresi. SSRI a SNRI jsou prvn\u00ed volbou, pokud je dominantn\u00edm probl\u00e9mem MDD.<\/p>\n

    Pro\u010d se Opiprol nepou\u017e\u00edv\u00e1 v USA nebo UK?<\/h3>\n

    Opipramol byl vyvinut ve \u0160v\u00fdcarsku v roce 1961 a v\u00fdrobci nikdy neusilovali o schv\u00e1len\u00ed FDA\/MHRA. Z\u016fst\u00e1v\u00e1 standardn\u00edm p\u0159edepisovan\u00fdm l\u00e9kem v N\u011bmecku, \u0160v\u00fdcarsku, Rakousku, Polsku, Turecku a dal\u0161\u00edch evropsk\u00fdch trz\u00edch.<\/p>\n

    Je Opiprol bezpe\u010dn\u011bj\u0161\u00ed ne\u017e benzodiazepiny p\u0159i dlouhodob\u00e9 l\u00e9\u010db\u011b \u00fazkosti?<\/h3>\n

    Ano \u2014 opipramol nem\u00e1 potenci\u00e1l vzniku z\u00e1vislosti, nehroz\u00ed zneu\u017eit\u00ed a po vysazen\u00ed nedoch\u00e1z\u00ed k rebound \u00fazkosti. Je rozumnou alternativou, kdy\u017e by benzodiazepiny p\u0159edstavovaly probl\u00e9m p\u0159i chronick\u00e9 generalizovan\u00e9 \u00fazkostn\u00e9 poru\u0161e.<\/p>\n

    Zp\u016fsob\u00ed Opiprol z\u00e1vislost nebo abstinen\u010dn\u00ed p\u0159\u00edznaky?<\/h3>\n

    Fyziologick\u00e1 z\u00e1vislost nen\u00ed zn\u00e1ma. P\u0159i n\u00e1hl\u00e9m vysazen\u00ed dlouhodob\u00e9 d\u00e1vky se mohou objevit m\u00edrn\u00e9 rebound nespavost nebo \u00fazkost \u2014 rozumn\u00e9 je postupn\u00e9 sni\u017eov\u00e1n\u00ed d\u00e1vky b\u011bhem 1\u20132 t\u00fddn\u016f.<\/p>\n

    Mohu p\u00edt alkohol p\u0159i u\u017e\u00edv\u00e1n\u00ed Opiprolu?<\/h3>\n

    Vyhn\u011bte se nadm\u011brn\u00e9mu pit\u00ed alkoholu \u2014 doch\u00e1z\u00ed k aditivn\u00edmu sedativn\u00edmu \u00fa\u010dinku. Ob\u010dasn\u00e1 konzumace mal\u00e9ho mno\u017estv\u00ed alkoholu je obvykle tolerov\u00e1na.<\/p>\n

    Je Opiprol bezpe\u010dn\u00fd v t\u011bhotenstv\u00ed?<\/h3>\n

    \u00dadaje o bezpe\u010dnosti jsou omezen\u00e9 \u2014 v t\u011bhotenstv\u00ed nen\u00ed preferov\u00e1n. Proberte alternativy s p\u0159edepisuj\u00edc\u00edm l\u00e9ka\u0159em.<\/p>\n

    Co se stane, kdy\u017e vynech\u00e1m d\u00e1vku?<\/h3>\n

    Vezm\u011bte si ho, jakmile si vzpomenete, pokud nen\u00ed bl\u00edzko dal\u0161\u00ed d\u00e1vky. Vynech\u00e1n\u00ed jedn\u00e9 d\u00e1vky z\u0159\u00eddka zp\u016fsob\u00ed probl\u00e9my vzhledem k dlouh\u00e9mu polo\u010dasu rozpadu.<\/p>\n

    Zp\u016fsob\u00ed Opiprol sexu\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky?<\/h3>\n

    M\u00e9n\u011b ne\u017e SSRI \u2014 opipramol se \u010dasto pou\u017e\u00edv\u00e1 jako alternativa p\u0159i nesnesiteln\u00e9 sexu\u00e1ln\u00ed dysfunkci vyvolan\u00e9 SSRI u pacient\u016f, jejich\u017e hlavn\u00edm probl\u00e9mem je \u00fazkost sp\u00ed\u0161e ne\u017e deprese.<\/p>\n

    Jak by m\u011bl b\u00fdt Opiprol skladov\u00e1n?<\/h3>\n

    Skladujte p\u0159i teplot\u011b 15\u201330 \u00b0C v p\u016fvodn\u00edm blistrov\u00e9m obalu, mimo dosah vlhkosti a slune\u010dn\u00edho sv\u011btla. Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/p>\n

    Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Informace na t\u00e9to str\u00e1nce jsou ur\u010deny dosp\u011bl\u00fdm u\u017e\u00edvaj\u00edc\u00edm p\u0159edepsan\u00e9 psychiatrick\u00e9 l\u00e9ky a nenahrazuj\u00ed individu\u00e1ln\u00ed l\u00e9ka\u0159skou p\u00e9\u010di. Antidepresiva, antipsychotika a p\u0159\u00edbuzn\u00e9 l\u00e9ky mohou interagovat s jin\u00fdmi l\u00e9ky, alkoholem a st\u00e1vaj\u00edc\u00edmi zdravotn\u00edmi stavy. Jak\u00e9koli nov\u00e9 l\u00e9ky, zm\u011bnu d\u00e1vkov\u00e1n\u00ed nebo pl\u00e1novan\u00e9 vysazen\u00ed konzultujte s kvalifikovan\u00fdm l\u00e9ka\u0159em. Pokud se u v\u00e1s objev\u00ed sebevra\u017eedn\u00e9 my\u0161lenky, m\u00e1nie, t\u011b\u017ek\u00e1 akathisie, p\u0159\u00edznaky serotoninov\u00e9ho syndromu (vysok\u00e1 hore\u010dka, zmatenost, svalov\u00e1 ztuhlost, zrychlen\u00fd srde\u010dn\u00ed tep) nebo neuroleptick\u00fd malign\u00ed syndrom, vyhledejte okam\u017eit\u011b l\u00e9ka\u0159skou pomoc.<\/div>\n

    <\/p>\n

    Souvisej\u00edc\u00ed alternativy<\/h3>\n

    Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n